Global Hurthle Cell Carcinoma Treatment Market, By Stages (Stage I, Stage II, Others), Type (Primary, Regional, Metastasized, Others), Treatment (Surgery, Radioactive Iodine Therapy, Radiation Therapy, Chemotherapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Industry Trends and Forecast to 2030.
Hurthle Cell Carcinoma Treatment Market Analysis and Size
The global hurthle cell carcinoma treatment market is expected to witness significant growth during the forecast period of 2023 to 2030. Rising prevalence of thyroid cancer, hyperthyroidism and other thyroid related diseases and different brand manufacturers will boost up the global hurthle cell carcinoma treatment market multiple treatment landscape and family history of hurthle cell carcinoma are considered as positive indicator for the demand of novel hurthle cell carcinoma drugs. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses that the global hurthle cell carcinoma treatment market which was USD 11,352.86 million in 2022, would rocket up to USD 16,514.76 million by 2030, and is expected to undergo a CAGR of 5.50% during the forecast period of 2023 to 2030. "Stage II" dominates the stage segment of the global hurthle cell carcinoma treatment market due to increasing diagnosis of hurthle cell carcinoma in stage II. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Hurthle Cell Carcinoma Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Stages (Stage I, Stage II, Others), Type (Primary, Regional, Metastasized, Others), Treatment (Surgery, Radioactive Iodine Therapy, Radiation Therapy, Chemotherapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa
|
|
Market Players Covered
|
Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Merck KGaA (Germany), Sun Pharmaceutical (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Amneal Pharmaceuticals LLC. (U.S.), Eisai Co., Ltd (Japan), Provell Pharmaceuticals, LLC (U.S.), Piramal Critical Care (India)
|
|
Market Opportunities
|
|
Market Definition
Hurthle cell carcinoma is the rare thyroid cancer that is considered the most aggressive type of thyroid cancer compared to other thyroid cancer. For the treatment surgery is the most feasible option. Although hurthle cell carcinoma doesn't always cause symptoms and it's sometimes detected during a physical examination or an imaging test. These symptoms incudes pain and lump in neck, hoarseness and change in voice, shortness of breath and swallowing difficulty. Females, geriatric population and patient having a history of radiation treatments to the head and neck are at major risk of getting hurthle cell carcinoma. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period of 2023 to 2030.
Global Hurthle Cell Carcinoma Treatment Market Dynamics
Drivers
- Increase in Elderly Population
The geriatric population is expected to increase the patient population globally, which boots the global hurthle cell carcinoma treatment market in the forecast period. According to the WHO, the global elderly population is expected to reach around 2 billion by 2050 from 617 million in 2015 and the possibility of getting infected with ovarian cancer also rises high. This will boost the market growth.
- Rising Demand of Oral Drug
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
- Increase in Hurthle Cell Carcinoma
Hurthle cell carcinoma is a widely invasive tumor than other thyroid tumors. This carcinoma is also associated with a high rate of distant metastases. It accounts for approximately about 4%–10% of differentiated thyroid cancers. This will boost the market growth.
Opportunity
- Rising Healthcare Awareness
Health awareness amongst the population are rising which results in the prediction of drugs boost the market growth. The innovative launches in medications for the treatment of ovarian cancer are expected to prompt the market simultaneously. Different researchers are investing in launching the drugs that benefit the market. This creates more opportunity in the market.
Restraint/Challenge
- Lack of Skilled Professionals
Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global hurthle cell carcinoma treatment market over a forecast period of 2023 to 2030.
This global hurthle cell carcinoma treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global hurthle cell carcinoma treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In May 2020, Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved Retevmo (selpercatinib, 40 mg and 80 mg capsules), the first therapy specifically indicated for the treatment of adult patients with metastatic rearranged during transfection (RET)
Global Hurthle Cell Carcinoma Treatment Market Scope
The global hurthle cell carcinoma treatment market is segmented on the basis of stages, type, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you meagre growth segments in the industries and provide the users with a valuable market overview and insights to help them make strategic decisions for identifying core market applications.
Stages
- Stage I
- Stage II
- Others
Type
- Primary
- Regional
- Metastasized
- Others
Treatment
- Surgery
- Radioactive Iodine Therapy
- Radiation Therapy
- Chemotherapy
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Specialty Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Global Hurthle Cell Carcinoma Treatment Market Regional Analysis/Insights
The global hurthle cell carcinoma treatment market is analysed and market size insights and trends are provided by country, stages, type, treatment, route of administration, end-users and distribution channel as referenced above.
The countries covered in the global hurthle cell carcinoma treatment market report is U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa
North America dominates the global hurthle cell carcinoma treatment market due to increasing thyroid related diseases, and increasing initiatives taken by the pharmaceutical organizations to generate novel formulation.
Asia-Pacific countries are expected to witness a significant growth in the global hurthle cell carcinoma treatment market during the forecast period of 2023 to 2030 due to development of healthcare infrastructure will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and domestic regulation changes that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Hurthle Cell Carcinoma Treatment Share Analysis
The global hurthle cell carcinoma treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global hurthle cell carcinoma treatment market.
Some of the major players operating in the global hurthle cell carcinoma treatment market are:
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. ( Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (U.S.)
- Merck & Co., Inc. (U.S.)
- Abbott (U.S.)
- AbbVie Inc. (U.S.)
- Merck KGaA (Germany)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Amneal Pharmaceuticals LLC. (U.S.)
- Eisai Co., Ltd (Japan)
- Provell Pharmaceuticals, LLC (U.S.)
- Piramal Critical Care (India)
SKU-